K562 R0.75
Homo sapiens
Protocols: Gradual dose escalation protocol was used to establish imatinib-resistant K562 cell lines. K562 cells resistant to 0.25 μM, 0.5 μM, and 0.75 μM imatinib were maintained in cRPMI medium and the respective imatinib concentration and parental K562 cells were maintained in cRPMI medium only. Imatinib resistance was checked on the IC50 value for imatinib obtained from MTT assay. DNA was extracted from imatinib-sensitive and -resistant K562 cells, using AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, MD, USA: catalogue no. 80224) according to the manufacturer's recommendations. WGS was performed on imatinib-sensitive and -resistant (to 0.25, 0.5, and 0.75 M imatinib) K562 cells. Library preparation was done by 30x WGS KAPA PCR-Free v2.1 kit, as per manufacturers instruction.
ENA-FIRST-PUBLIC
2024-01-01T01:01:11Z
ENA-LAST-UPDATE
2024-01-01T01:01:11Z
External Id
SAMEA110196432
INSDC center name
Tata Memorial Centre - Advanced Centre for Treatment, Research and Education in Cancer
INSDC first public
2024-01-01T01:01:11Z
INSDC last update
2024-01-01T01:01:11Z
INSDC status
public
Submitter Id
E-MTAB-11896:K562 R0.75
broker name
ArrayExpress
cell_line
K562
cell_type
hematopoietic cell
common name
human
disease
chronic myelogenous leukemia
isolate
not applicable
sample name
E-MTAB-11896:K562 R0.75
scientific_name
Homo sapiens